Ignite Creation Date:
2024-05-06 @ 3:57 AM
Last Modification Date:
2024-10-26 @ 11:41 AM
Study NCT ID:
NCT02414009
Status:
COMPLETED
Last Update Posted:
2021-09-09
First Post:
2015-02-05
Brief Title:
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced Colorectal Cancer Patients
Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori Milano
Organization:
Fondazione IRCCS Istituto Nazionale dei Tumori Milano
Study Overview
Official Title:
Open-label Randomized Multicenter Phase II Trial to Compare Efficacy of CAPTEM Versus FOLFIRI as Second Line in Patients Progressed on or After First-line Oxaliplatin Chemo for Advanced MGMT Methylated RAS Mutated Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAPTEM
Brief Summary:
Open-label randomized multicenter Phase II trial designed to estimate the efficacy of CAPTEM versus FOLFIRI as second line treatment in MGMT methylated RAS mutated advanced CRC patients who have progressed on or after first-line oxaliplatin containing chemotherapy for metastatic disease MGMT will be assessed centrally at Pathology Department of Fondazione IRCCS Istituto Nazionale dei Tumori prior to enrollment A minimum of ten 3-micron unstained sections on charged slides of tumor will be required and methylation status will be provided within a maximum of seven days to the Study Centers Presence of RAS mutation will be assessed at each local participating center Eligible patients will be randomized in a 11 ratio to one of two treatment arms
Arm A experimental arm CAPTEM
Arm B control arm FOLFIRI Study treatment will be given in cycles repeated every 28 days for Arm A and every 14 days for Arm B Patients in Arm A will receive capecitabine at the oral dose of 1500 mgmqdie bid from day 1 to day 14 every 28 days plus temozolomide 150 mgmqdie bid starting on day 9 to 14 every 28 days Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w every cycle starting on Day 1 of Cycle 1 FOLFIRI consists of irinotecan starting dose of 180 mgm2 on day one only 5-FU 7 starting bolus and 22-hour infusional doses of 400 mgm2 and 600 mgm2 respectively and leucovorin racemic starting dose of 200 mgm2 or L-form starting dose of 100 mgm2 for two consecutive days Treatment will continue for up to 6 cycles in Arm A and up to 12 cycles in Arm B or up to disease progression unacceptable toxicity or informed consent withdrawal Randomization will be stratified across the treatment arms by the following predefined stratification variables disease progression within 9 months from the start of first-line oxaliplatin-containing chemotherapy vs 9 months prior bevacizumab in combination with oxaliplatin-based chemotherapy yes vs no Efficacy assessments will be performed every 2 cycles in Arm A and every 4 cycles in Arm B until progression The study is expected to enrol approximately 82 patients who meet the eligibility criteria
Arm A experimental arm CAPTEM
Arm B control arm FOLFIRI Study treatment will be given in cycles repeated every 28 days for Arm A and every 14 days for Arm B Patients in Arm A will receive capecitabine at the oral dose of 1500 mgmqdie bid from day 1 to day 14 every 28 days plus temozolomide 150 mgmqdie bid starting on day 9 to 14 every 28 days Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w every cycle starting on Day 1 of Cycle 1 FOLFIRI consists of irinotecan starting dose of 180 mgm2 on day one only 5-FU 7 starting bolus and 22-hour infusional doses of 400 mgm2 and 600 mgm2 respectively and leucovorin racemic starting dose of 200 mgm2 or L-form starting dose of 100 mgm2 for two consecutive days Treatment will continue for up to 6 cycles in Arm A and up to 12 cycles in Arm B or up to disease progression unacceptable toxicity or informed consent withdrawal Randomization will be stratified across the treatment arms by the following predefined stratification variables disease progression within 9 months from the start of first-line oxaliplatin-containing chemotherapy vs 9 months prior bevacizumab in combination with oxaliplatin-based chemotherapy yes vs no Efficacy assessments will be performed every 2 cycles in Arm A and every 4 cycles in Arm B until progression The study is expected to enrol approximately 82 patients who meet the eligibility criteria
Detailed Description:
Colorectal cancer CRC is the third most commonly diagnosed cancer in males and the second in females with over 12 million new cancer cases and 608700 deaths estimated to have occurred in 2008 Approximately 35 of CRC patients present a Stage IV metastatic disease at the time of diagnosis and 20-50 of Stage II or III disease will progress to Stage IV at some point during the course of disease Stage IV CRC carries a dismal prognosis the 5-year survival rate is 10 and median survival time of patients given optimal supportive care without chemotherapy is approximately 5 months Hypothesisrationale In advanced CRC the occurrence of chemo- refractory disease poses a major therapeutic challenge for presence of an adequate performance status to potentially receive further treatments but absence of effective drugs which may be offered to patients with an evidence-based algorithm Patients who progress after all approved treatments may be generally considered suitable for new investigational drugs or strategies Thus in the era of personalized medicine tumor molecular profiling may lead to the identification of therapeutic targets or predictive biomarkers for pharmacological intervention The DNA repair gene O6-methylguanine-DNA methyltransferase MGMT is responsible of the elimination of alkyl groups from the O6-position of guanine If inactive it may be involved in early steps of colorectal tumorigenesis through an increase of the mutational rate particularly G-to-A point mutations of KRAS gene Epigenetic silencing of MGMT during colorectal tumorigenesis is associated with hypermethylation of the CpG island in its promoter This transcriptional gene silencing is responsible for diminished DNA-repair of O6-alkylguanine adducts with the consequence of enhancing chemosensitivity to alkylating agents in particular dacarbazine and its oral prodrug temozolomide In a previous phase II study the investigators showed that temozolomide induced an objective response rate by RECIST criteria in 12 of heavily pretreated patients with advanced CRC and MGMT promoter 6 methylation Treatment was well tolerated and the only grade 4 toxicity was one thrombocytopenia episode 3 The trial met its primary end point of acceptable response rate with a disease control rate of 31 a median PFS progression free survival and OS overall survival of 18 and 84 months respectively Other studies in carcinoids cell lines demonstrated synergistic cell kill if 5-FU 5-fluorouracil and TMZ temozolomide were delivered in a schedule-dependent manner From these translational studies it has been formulated the CAPTEM regimen using TMZ for 5 days at 150-200 mgm2day total daily dose on days 10-14 given in BID oral dosing with capecitabine 750 mgm2 PO per OS BID on days 1-14 of a 28-day cycle The use of TMZ in BID BIS in DIE dosing instead of daily dosing was done because the first dose binds 6-MGMT levels thus allowing the second dose to methylate guanines with decreased repair from MGMT Given the potential synergy of CAPTEM combination in CRC the investigators planned a randomized study of second-line CAPTEM vs FOLFIRI after failure of prior first-line oxaliplatin - based treatment Study design Open-label randomized multicenter Phase II trial designed to estimate the efficacy of CAPTEM versus FOLFIRI as second line treatment in MGMT methylated RAS mutated advanced CRC patients who have progressed on or after first-line oxaliplatin containing chemotherapy for metastatic disease MGMT will be assessed centrally at Pathology Department of Fondazione IRCCS Istituto Nazionale dei Tumori prior to enrollment A minimum of ten 3-micron unstained sections on charged slides of tumor will be required and methylation status will be provided within a maximum of seven days to the Study Centers Presence of RAS mutation will be assessed at each local participating center Eligible patients will be randomized in a 11 ratio to one of two treatment arms
Arm A experimental arm CAPTEM
Arm B control arm FOLFIRI Study treatment will be given in cycles repeated every 28 days for Arm A and every 14 days for Arm B Patients in Arm A will receive capecitabine at the oral dose of 1500 mgmqdie bid from day 1 to day 14 every 28 days plus temozolomide 150 mgmqdie bid starting on day 10 to 14 every 28 days Patients in Arm B will receive FOLFIRI chemotherapy starting Day
1 q2w every cycle starting on Day 1 of Cycle 1 FOLFIRI consists of irinotecan starting dose of 180 mgm2 on day one only 5-FU 7 starting bolus and 22-hour infusional doses of 400 mgm2 and 600 mgm2 respectively and leucovorin racemic starting dose of 200 mgm2 or L-form starting dose of 100 mgm2 for two consecutive days Treatment will continue for up to 6 cycles in Arm A and up to 12 cycles in Arm B or up to disease progression unacceptable toxicity or informed consent withdrawal Randomization will be stratified across the treatment arms by the following predefined stratification variables disease progression within 9 months from the start of first-line oxaliplatin-containing chemotherapy vs 9 months prior bevacizumab in combination with oxaliplatin-based chemotherapy yes vs no Efficacy assessments will be performed every 2 cycles in Arm A and every 4 cycles in Arm B until progression The study is expected to enrol approximately 82 patients who meet the eligibility criteria Number of study centres 10 centers in Italy Primary objective and corresponding end point
To evaluate the efficacy as measured by progression-free survival of FOLFIRI administered every 2 weeks versus CAPTEM administered four-weekly Secondary objectives and corresponding end points
To evaluate the activity of the two regimens as measured by response rate secondary efficacy endpoints also include duration of response and overall survival of FOLFIRI administered every 2 weeks versus CAPTEM administered four-weekly
To evaluate the safety of FOLFIRI versus CAPTEM
To assess the quality of life as measured by Quality of life questionnaires EORTC QLQ - CR29 QLQ-C30 Statistical methodology According to the published results of the GERCOR study the median progression-free survival during second-line treatment with crossover from FOLFOX to FOLFIRI was 23 months calculated from the start of second-line treatment with FOLFIRI A one-sided log rank test with an overall sample size of 82 subjects 41 in the control group and 41 in the study group achieves 90 power at a 5 significance level to detect an increase in median progression free survival from 2 months of the control group to 4 months The study lasts for 30 months of which subject accrual entry occurs in 24 months
Arm A experimental arm CAPTEM
Arm B control arm FOLFIRI Study treatment will be given in cycles repeated every 28 days for Arm A and every 14 days for Arm B Patients in Arm A will receive capecitabine at the oral dose of 1500 mgmqdie bid from day 1 to day 14 every 28 days plus temozolomide 150 mgmqdie bid starting on day 10 to 14 every 28 days Patients in Arm B will receive FOLFIRI chemotherapy starting Day
1 q2w every cycle starting on Day 1 of Cycle 1 FOLFIRI consists of irinotecan starting dose of 180 mgm2 on day one only 5-FU 7 starting bolus and 22-hour infusional doses of 400 mgm2 and 600 mgm2 respectively and leucovorin racemic starting dose of 200 mgm2 or L-form starting dose of 100 mgm2 for two consecutive days Treatment will continue for up to 6 cycles in Arm A and up to 12 cycles in Arm B or up to disease progression unacceptable toxicity or informed consent withdrawal Randomization will be stratified across the treatment arms by the following predefined stratification variables disease progression within 9 months from the start of first-line oxaliplatin-containing chemotherapy vs 9 months prior bevacizumab in combination with oxaliplatin-based chemotherapy yes vs no Efficacy assessments will be performed every 2 cycles in Arm A and every 4 cycles in Arm B until progression The study is expected to enrol approximately 82 patients who meet the eligibility criteria Number of study centres 10 centers in Italy Primary objective and corresponding end point
To evaluate the efficacy as measured by progression-free survival of FOLFIRI administered every 2 weeks versus CAPTEM administered four-weekly Secondary objectives and corresponding end points
To evaluate the activity of the two regimens as measured by response rate secondary efficacy endpoints also include duration of response and overall survival of FOLFIRI administered every 2 weeks versus CAPTEM administered four-weekly
To evaluate the safety of FOLFIRI versus CAPTEM
To assess the quality of life as measured by Quality of life questionnaires EORTC QLQ - CR29 QLQ-C30 Statistical methodology According to the published results of the GERCOR study the median progression-free survival during second-line treatment with crossover from FOLFOX to FOLFIRI was 23 months calculated from the start of second-line treatment with FOLFIRI A one-sided log rank test with an overall sample size of 82 subjects 41 in the control group and 41 in the study group achieves 90 power at a 5 significance level to detect an increase in median progression free survival from 2 months of the control group to 4 months The study lasts for 30 months of which subject accrual entry occurs in 24 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None